Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luke Pesonen

Vascular Surgery La Crosse, WI Medical Doctor

NPI 1689092652 CMS profile 4223969

1836 South Ave, Apt 30, La Crosse, WI 54601

Open in the dashboard

General payments

$3,896

37 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luke Pesonen of La Crosse, WI is reported in the CMS Open Payments database as having received $3,896 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,417 15
2024 General $159 3
2023 General $114 4
2022 General $402 6
2021 General $474 4
2020 General $981 3
2019 General $349 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luke Pesonen
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Luke Pesonen were reported at $1,417. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Luke Pesonen Vascular Surgery median Middle half National median
2019 $349 $796 $226–$2,363 $163
2020 $981 $348 $118–$1,110 $114
2021 $474 $471 $158–$1,421 $132
2022 $402 $725 $222–$2,183 $149
2023 $114 $836 $257–$2,440 $160
2024 $159 $909 $252–$2,619 $164
2025 $1,417 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $1,842 22 payments
  2. Medtronic Vascular, Inc. $1,330 5 payments
  3. Medtronic, Inc. $342 5 payments
  4. Abbott Laboratories $192 1 payment
  5. Silk Road Medical, Inc. $66 1 payment
  6. Shockwave Medical, Inc $64 1 payment
  7. Terumo Medical Corporation $61 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,751 29 payments
  2. Travel and Lodging $846 4 payments
  3. Education $681 3 payments
  4. Grant $618 1 payment
Products named General payments · program years 2019–2025
  1. Endurant Aortic Stent Grafts $914 3 payments
  2. GORE TAG Thoracic Branch Endoprosthesis $747 4 payments
  3. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $459 8 payments
  4. GORE EXCLUDER AAA Endoprosthesis $359 3 payments
  5. Endurant Aortic Stent Grafts $282 3 payments
  6. MVP $225 1 payment
  7. Supera peripheral stent system $192 1 payment
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $129 3 payments
  9. GORE VIABAHN Endoprosthesis with Heparin $91 1 payment
  10. ENROUTE Transcarotid Neuroprotection System $66 1 payment
  11. Other $480 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

129

Median for Vascular Surgery: 122

Drug cost

$1,248

Median for Vascular Surgery: $14,135

Branded share of claims

36.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 35 $454
Atorvastatin Calcium Generic 21 $341
Methocarbamol Generic 13 $179
Gabapentin Generic 13 $171
Oxycodone Hcl Generic 22 $47
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $29
Tramadol Hcl Generic 13 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$67,674

Medicare's payments for the services billed

Medicare patients

194

Average age 73

Services billed

585

67 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 53%
Ischemic heart disease 49%
Diabetes 45%
Heart failure 37%
Arthritis 37%
Atrial fibrillation 29%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record